An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

NCT05166070 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: RD133

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]